Waters Corp
XMUN:WAZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Waters Corp
XMUN:WAZ
|
US |
|
W
|
Wilmar International Ltd
OTC:WLMIY
|
SG |
|
C
|
Cooper-Standard Holdings Inc
SWB:C31
|
US |
|
T
|
TJX Companies Inc
DUS:TJX
|
US |
|
B
|
Bank Central Asia Tbk PT
OTC:PBCRF
|
ID |
|
K
|
Kao Corp
XMUN:KAO
|
JP |
|
Hongkong Land Holdings Ltd
OTC:HNGKY
|
BM |
|
Ferrari NV
NYSE:RACE
|
IT |
|
I
|
Ithaca Energy PLC
LSE:ITH
|
UK |
|
S
|
SunCoke Energy Inc
SWB:S01
|
US |
|
Guaranty Trust Holding Company PLC
F:9JO
|
NG |
|
Avenue Supermarts Ltd
NSE:DMART
|
IN |
|
Wyndham Hotels & Resorts Inc
NYSE:WH
|
US |
|
M
|
Main Street Capital Corp
SWB:13M
|
US |
|
A
|
Audax Renovables SA
SWB:54F
|
ES |
|
C
|
China Coal Energy Co Ltd
XHAM:CVV
|
CN |
|
H
|
Hongkong Land Holdings Ltd
F:HLH
|
BM |
|
Tesla Inc
NASDAQ:TSLA
|
US |
|
Marubeni Corp
TSE:8002
|
JP |
Waters Corp
Waters Corporation makes scientific instruments and lab software that help customers identify, measure, and separate chemicals in complex samples. Its main products are liquid chromatography systems, mass spectrometry systems, and the columns, spare parts, and software that go with them. These tools are used when labs need precise answers about what is in a drug, food, chemical, or biological sample. Its main customers are pharmaceutical and biotech companies, contract research labs, universities, government labs, and some industrial testing labs. Waters sells instruments upfront and then earns repeat business from consumable products like columns and from service, maintenance, and software. That mix gives the company both equipment sales and a steadier follow-on revenue stream tied to how much customers use the instruments. Waters sits in an important spot in the scientific testing chain: it helps labs move from raw samples to reliable data they can use for research, quality control, and regulatory work. It is not selling the drug or chemical itself; it sells the measurement tools that prove what that product contains and whether it meets standards. That makes the business closely linked to long-term spending on drug development, lab testing, and regulated manufacturing.
Waters Corporation makes scientific instruments and lab software that help customers identify, measure, and separate chemicals in complex samples. Its main products are liquid chromatography systems, mass spectrometry systems, and the columns, spare parts, and software that go with them. These tools are used when labs need precise answers about what is in a drug, food, chemical, or biological sample.
Its main customers are pharmaceutical and biotech companies, contract research labs, universities, government labs, and some industrial testing labs. Waters sells instruments upfront and then earns repeat business from consumable products like columns and from service, maintenance, and software. That mix gives the company both equipment sales and a steadier follow-on revenue stream tied to how much customers use the instruments.
Waters sits in an important spot in the scientific testing chain: it helps labs move from raw samples to reliable data they can use for research, quality control, and regulatory work. It is not selling the drug or chemical itself; it sells the measurement tools that prove what that product contains and whether it meets standards. That makes the business closely linked to long-term spending on drug development, lab testing, and regulated manufacturing.
Beat and raise: Waters said second-quarter revenue and EPS came in above guidance, and management raised full-year 2026 guidance across organic growth, acquired-business revenue, and EPS.
Strong momentum: Organic revenue grew 9% in constant currency, with orders outpacing sales and broad-based strength across pharma, academic/government, and industrial end markets.
BD integration ahead: The acquired Biosciences and Diagnostic Solutions businesses accelerated to 4% reported growth in the quarter, helped by pricing actions, better commercial execution, and early product launches.
Margins and cost actions: Waters completed its planned 2026 cost actions and now expects about $75 million of cumulative savings this year, supporting margin progression in the second half.
New products: Management highlighted launches including Cyclic IMS P20, Xevo MRT P10, FACSDiscover A7, and BACTEC FXI as key growth drivers.
China and reshoring: China improved in several areas, especially flow research and diagnostics, while management also pointed to U.S. pharma reshoring as a multi-year instrument opportunity.